The coronavirus disease 2019 (COVID-19) pandemic is having a catastrophic impact on human health1. Widespread community transmission has triggered stringent distancing measures with severe socio-economic consequences. Gaining control of the pandemic will depend on the interruption of transmission chains until vaccine-induced or naturally acquired protective herd immunity arises. However, approved antiviral treatments such as remdesivir and reconvalescent serum cannot be delivered orally2,3, making them poorly suitable for transmission control. We previously reported the development of an orally efficacious ribonucleoside analogue inhibitor of influenza viruses, MK-4482/EIDD-2801 (refs. 4,5), that was repurposed for use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is currently in phase II/III clinical trials (NCT04405570 and NCT04405739). Here, we explored the efficacy of therapeutically administered MK-4482/EIDD-2801 to mitigate SARS-CoV-2 infection and block transmission in the ferret model, given that ferrets and related members of the weasel genus transmit the virus efficiently with minimal clinical signs6,7,8,9, which resembles the spread in the human young-adult population. We demonstrate high SARS-CoV-2 burden in nasal tissues and secretions, which coincided with efficient transmission through direct contact. Therapeutic treatment of infected animals with MK-4482/EIDD-2801 twice a day significantly reduced the SARS-CoV-2 load in the upper respiratory tract and completely suppressed spread to untreated contact animals. This study identified oral MK-4482/EIDD-2801 as a promising antiviral countermeasure to break SARS-CoV-2 community transmission chains.
MK-4482/EIDD-2801 is the orally available pro-drug of the nucleoside analogue N4-hydroxycytidine (NHC), which has shown potent anti-influenza virus activity in mice, guinea pigs, ferrets and human airway epithelium organoids4,10,11. Acting through the induction of error catastrophe in virus replication4,12, NHC has broad-spectrum anti-RNA virus activity. In addition to ameliorating acute disease, we have demonstrated in a guinea pig transmission model that NHC effectively blocks the spread of influenza virus from infected animals to untreated contact animals11.
Several mouse models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been developed, some of which were also employed to confirm the in vivo efficacy of MK-4482/EIDD-2801 against betacoronaviruses13. However, human SARS-CoV-2 cannot productively infect mice without viral adaptation or introduction of human ACE2 into transgenic animals, and none of the mouse models support transmission to uninfected mice14. Spill-back of SARS-CoV-2 to farmed minks, subsequent large-scale mink-to-mink transmission and, in some cases, zoonotic transmission back to humans revealed efficient viral spread among members of the weasel genus without previous adaptation6,7,8,9. Although mink farms reported elevated animal mortality and gastrointestinal and respiratory clinical signs15, outbreak follow-up revealed continued intra-colony spread for extended periods of time9, suggesting that the acute clinical signs in the majority of infected animals may be mild. These mink field reports corroborated results obtained with experimentally infected ferrets showing that mustelids of the weasel genus transmit SARS-CoV-2 efficiently without strong clinical disease manifestation16,17. As this presentation of SARS-CoV-2 infection resembles the experience of frequently asymptomatic or mildly symptomatic SARS-CoV-2 spread in the human young-adult population18, ferrets represent a relevant model species to assess therapeutic impact on SARS-CoV-2 transmission.
To first validate host invasion and tissue tropism of SARS-CoV-2 in ferrets, we inoculated animals intranasally with either 1 × 104 or 1 × 105 plaque-forming units (p.f.u.)—low- and high-inoculum group, respectively—of SARS-CoV-2 clinical isolate 2019-nCoV/USA-WA1/2020 per animal. The shed virus burden was monitored daily over a period of 10 d. The virus load in the upper and lower respiratory tract was determined for two animals from each inoculum group on days four and ten after infection, respectively.
Virus release from the upper respiratory tract peaked three days after infection and was undetectable by day seven in the animals of the high-inoculum group (Fig. 1a and Supplementary Table 1). Infection of animals in the low-inoculum group was less efficient. The shedding profiles correlated closely with the infectious particle load in nasal turbinates; a heavy virus tissue burden in the high-inoculum group was present on day four, which decreased substantially by approximately four orders of magnitude by day ten (Fig. 1b and Supplementary Table 2).
Infection with a low concentration of inoculum resulted in low virus loads in the turbinates on day 4 and undetectable burden thereafter. However, quantitation of viral RNA copy numbers in the turbinates using RT–qPCR revealed the continued presence of moderate (approximately 104 copies g−1 tissue) to high (≥107 copies g−1 tissue) virus loads in the groups with low and high inoculums, respectively (Fig. 1c and Supplementary Table 3). Irrespective of the inoculum concentration, no infectious particles were detected in bronchoalveolar lavages or lung tissue samples (Extended Data Fig. 1). Several organ samples (lungs, heart, kidneys and liver) were also RT–qPCR-negative on both days 4 and 10 (Fig. 1d), confirming inefficient infection of the ferret lower respiratory tract and limited systemic host invasion. Only the small and large intestine samples were PCR-positive on day 4 after infection, and rectal swabs showed continued low-grade shedding of viral genetic material (Fig. 1e and Supplementary Table 4).
The animals in the high-inoculum group experienced a transient drop in body weight that reached a low plateau on days 5–6 after infection but recovered fully by the end of the study (Fig. 1f and Supplementary Table 5). One animal in the low-inoculum group showed a gradual slight reduction in body weight until the end of the study (day 10). No other clinical signs, such as fever or respiratory discharge, were noted. The complete blood counts (CBCs) taken every second day revealed no significant deterioration from the normal range in the overall white-blood-cell counts as well as lymphocyte, neutrophil and platelet populations of either inoculum group (Fig. 1g and Supplementary Table 6). The relative expression levels of type I and II interferon in the ferret peripheral blood mononuclear cells (PBMCs) sampled at 48-h intervals reached a plateau approximately 3 d after infection and stayed moderately elevated until the end of the study (Fig. 1h,i and Supplementary Table 7). IL-6 levels were moderately elevated in some animals but these changes did not reach statistical significance (Fig. 1j). However, we noted a prominent expression peak of select interferon-stimulated genes (ISGs) with antiviral effector function (MX1 and ISG15) 4 d after infection, followed by a return to baseline expression by the end of the study (Fig. 1k,l).
Before in vivo efficacy evaluation, we validated the potency of NHC against the SARS-CoV-2 clinical isolate 2019-nCoV/USA-WA1/2020 in cell culture (Fig. 2a). Four-parameter variable slope regression modelling of the dose-response data revealed 50 and 90% effective concentrations (EC50 and EC90, respectively) of approximately 3.4 µM and 5.4 µM, respectively, which is within an approximately sixfold range of potency data reported for other human betacoronaviruses19. Based on these results, ferrets were infected with 1 × 105 p.f.u. per animal in the subsequent MK-4482/EIDD-2801 efficacy tests and the levels of infectious virions in nasal lavages were determined twice daily (Fig. 2b). The viral burden in respiratory tissues was assessed 4 d after infection. In all treatment experiments, MK-4482/EIDD-2801 was administered twice a day (b.i.d.) through oral gavage. Dosing commenced 12 h after infection at 5 or 15 mg kg−1 body weight, or 36 h after infection at 15 mg kg−1. The titres of shed virus in the nasal lavages were equivalent in all MK-4482/EIDD-2801 groups and vehicle-treated controls at the time of the first treatment (12 h after infection), indicating uniform inoculation of all animals in the study (Fig. 2c and Extended Data Fig. 2a). Initiation of therapy at the 12-h time point resulted in a significant reduction (P < 0.001) of the shed virus load within 12 h, independently of the MK-4482/EIDD-2801 dose administered, and infectious particles became undetectable within 24 h of the start of treatment. When first administered at the peak of virus shedding (36 h after infection), MK-4482/EIDD-2801 completely suppressed the release of infectious virions into nasal lavages within a slightly longer period of 36 h, whereas the vehicle control animals continued to shed infectious particles until the study end.
Only the vehicle-treated animals carried detectable virus burden in their nasal turbinates 3.5 d after infection (Fig. 2d and Extended Data Fig. 2b), indicating that MK-4482/EIDD-2801 had silenced all SARS-CoV-2 replication. SARS-CoV-2 RNA was still detectable in the nasal tissues extracted from animals in all groups, albeit significantly reduced (P = 0.0089 and 0.0081 for the 5 and 15 mg kg−1 MK-4482/EIDD-2801 groups, respectively) in the treated animals versus the vehicle controls (Fig. 2e and Extended Data Fig. 2c). The animals in the 12-h therapeutic groups showed a significant reduction (P ≤ 0.044) in effector ISG expression compared with the vehicle-treated animals, although no significant differences in relative interferon and IL-6 induction were observed (Extended Data Fig. 3a–f).
These results demonstrate the oral efficacy of therapeutic administration of MK-4482/EIDD-2801 against acute SARS-CoV-2 infection in the ferret model. Consistent with our previous pharmacokinetic and toxicology work-up of MK-4482/EIDD-2801 in ferrets, treatment did not cause any phenotypically overt adverse effects, and the white-blood-cell and platelet counts of the drug-experienced animals remained within the normal range (Extended Data Fig. 4).
SARS-CoV-2 shedding into the upper respiratory tract of ferrets establishes conditions for the productive spread from the infected source to uninfected contact animals16,17. To assess transmission efficiency, we co-housed intranasally infected source animals with two uninfected contact animals each for a period of 3 d, starting 30 h after the inoculation of the source animal (Fig. 3a). Nasal lavages and rectal swabs were obtained daily from all of the animals and blood was sampled at the start of the study and on days four and eight after the original infection. The viral burden and RNA copy numbers in the respiratory tissues were determined at the end of the co-housing phase (source animals) and at study termination (contact animals).
Infectious particles first emerged in the nasal lavages of some contact animals 24 h after the start of co-housing (Fig. 3b and Supplementary Table 8). By the end of the co-housing phase, all contact animals were infected and approached the peak virus-replication phase, demonstrating that transmission of SARS-CoV-2 among ferrets is rapid and highly efficient.
A second cohort of source animals inoculated in parallel with SARS-CoV-2 received oral MK-4482/EIDD-2801 at a dose of 5 mg kg−1 body weight, administered b.i.d. starting 12 h after infection. Productive infection of these animals was validated by the titres of SARS-CoV-2 in the nasal lavages 1 d after infection (Fig. 3b), which very closely matched those seen in the initial efficacy tests (Fig. 2c). Although we also co-housed the treated source animals with two untreated contacts each for nearly 3 d, no infectious SARS-CoV-2 particles were detected in any of the series of nasal lavages obtained from these contacts throughout the study or in any of the nasal turbinates sampled from the contact animal at end of the study (Fig. 3c and Supplementary Table 9).
The nasal turbinates extracted from the contacts of the vehicle-treated source animals contained high copy numbers of viral RNA, underscoring successful host invasion after transmission (Fig. 3d and Supplementary Table 10). Consistent with our earlier observations, the turbinates of the treated source animals harboured moderate-to-high (≥105 copies g−1 tissue) levels of viral RNA, although infectious particles could not be detected. In contrast, all respiratory tissues of the contacts co-housed with the source animals treated with MK-4482/EIDD-2801 remained SARS-CoV-2-genome free, indicating an absence of any low-grade virus replication that could have hypothetically progressed in these animals below the detection level of infectious particles (Fig. 3e,f and Supplementary Tables 11,12). Furthermore, SARS-CoV-2 RNA was present at low copy numbers in the intestinal tissue samples and rectal swabs of the vehicle source animals as well as their contacts but undetectable in the MK-4482/EIDD-2801-treated source group and co-housed contact animals.
Phylogenetic analysis of outbreaks in mink farms revealed prolonged intra-colony circulation and zoonotic mink-to-human transmission9, leading us to select ferrets—members of the weasel genus closely related to minks—as a SARS-CoV-2 transmission model. We noted that the experimental infection of ferrets was strongly dependent on the amount of viral inoculum used. Productive host invasion was only observed after intranasal delivery of 1 × 105 p.f.u. SARS-CoV-2. The shed SARS-CoV-2 load in ferret nasal lavages, a core virological marker of a transmission model, showed good cross-study consistency. Our experiments returned peak shed virus titres of 1 × 103–1 × 104 p.f.u. ml−1, closely resembling the ferret lavage titres found in two previous studies, which reported up to 1 × 104 p.f.u. ml−1 (ref. 20) and 1 × 103 median tissue culture infectious dose ml−1 (ref. 21) in nasal lavages, respectively.
Natural infection through direct contact was highly efficient, possibly reflecting the prolonged exposure of contact to source animals in a confined space. However, nearly all contacts started to shed virus within less than 24 h after the beginning of co-housing. This timeline indicates that transmission must have occurred shortly after the introduction of contact to the source animals, despite the fact that the shed viral titres of the source animals were only 1 × 103 p.f.u. ml−1 nasal lavage in this disease period. Transmission of SARS-CoV-2 between ferrets through the air has recently been demonstrated22. Our results underscore that natural infection with SARS-CoV-2 through large droplets, aerosols and/or fomites is highly productive.
MK-4482/EIDD-2801 is currently being tested in advanced multi-centre clinical trials, which were launched after the successful completion of phase I safety trials (that is, NCT04392219). Although the dosages applied in these studies and human pharmacokinetic data have not yet been disclosed, Merck & Co. have revealed23 that NHC reached levels in human blood that were safe and exceeded antiviral concentrations against SARS-CoV-2 in primary human airway epithelia cultures (NHC EC90 of approximately 0.5–1 μM; ref. 13). Our pharmacokinetic profiles for MK-4482/EIDD-2801 revealed that NHC plasma concentrations ≥0.5 μM at trough (12 h after dosing based on a b.i.d. regimen) are reached after oral doses of approximately 130 and 10 mg kg−1 were administered to cynomolgus macaques and ferrets, respectively4. These calculations drove our decision to dose ferrets with the 5 mg kg−1 dose used in this study, which represents a conservative estimate of a safe human-dose equivalent based on all of the available information. Underscoring the high broad-spectrum antiviral potential of the drug, 5 mg kg−1 is also close to the lowest efficacious dose of MK-4482/EIDD-2801 against seasonal and pandemic influenza viruses in ferrets4,10.
Closely resembling our previous experience with influenza therapy4,10, MK-4482/EIDD-2801 was well tolerated and orally efficacious against SARS-CoV-2, reducing the upper respiratory virus load to below the detection level within 24 h of the first drug administration when therapy was initiated after the onset of virus shedding and by nearly two orders of magnitude when first administered at the peak of virus replication. Similarly, viral genetic material was undetectable in the gastrointestinal samples of the treated animals, which is consistent with previous observations of a sustained presence of the biologically active triphosphate form of NHC in all soft tissue, except liver, in different species4,12,24.
Importantly, treatment suppressed all transmission to the untreated direct contacts despite a prolonged direct proximity of the source and contact animals as well as detectable virus shedding from the source animals at the beginning of the co-housing phase. This complete block may indicate a bottom threshold of the shed SARS-CoV-2 load for successful spread. In addition, the genome integrity of some EIDD-2801-experienced virions shed from the treated animals may have been only partially compromised. Rather than being chain-terminating when incorporated by the viral polymerase, NHC undergoes spontaneous tautomeric interconversions, leading to base pairing either as cytosine or uracil25. The resulting randomly positioned transition mutations induce viral error catastrophe26, causing a collapse of the virus population. This mechanism of antiviral activity of NHC was demonstrated for alphaviruses12, pneumoviruses11 and orthomyxoviruses4, and confirmed to equally apply to betacoronaviruses19 and specifically SARS-CoVs13. In our study, a limited presence of the analogue in the viral genomes generated shortly after the start of treatment may have had a greater impact on natural invasion of an immune-competent host in vivo than on virus replication in type I interferon-deficient cultured cells such as the Vero E6 used for titration27. This view is consistent with the frequent observation (such as in ref. 28) that many mutant viruses can be propagated in cell culture but are attenuated in vivo and incapable of productive host invasion.
Consistent with the conserved antiviral mechanism of action of NHC across diverse viral targets, several previous attempts to induce robust resistance to the compound in alphaviruses12, orthomyxoviruses4 and betacoronaviruses19 were unsuccessful, indicating a high genetic barrier against viral escape. For betacoronaviruses specifically, a very moderate twofold increase in the EC90 concentration was reported after 30 passages in the presence of inhibitor19. Given that these mutations delayed viral replication and thus posed a fitness penalty, it is unlikely that clinical use of MK-4482/EIDD-2801 will result in the emergence of pre-existing resistance in circulating virus populations or trigger the appearance of viral variants with enhanced pathogenicity.
Our previous studies with influenza viruses in ferrets4 and guinea pigs11 furthermore demonstrate that the antiviral efficacy and transmission block by MK-4482/EIDD-2801 are not host-species restricted. A virological study of hospitalized patients with coronavirus disease 2019 (COVID-19) revealed that the average load of SARS-CoV-2 RNA copies detected in human sputum during the peak phase of infection is 7.0 × 106 copies ml−1 (maximum of 2.35 × 109 copies ml−1)29. Attempts at virus isolation from human patients were generally unsuccessful when the samples contained <1 × 106 RNA copies ml−1. In ferrets, we found peak shedding titres of 1 × 103–1 × 104 p.f.u. ml−1 in the nasal lavages and an earlier study reported that SARS-CoV-2 concentrations of up to 1 × 104 p.f.u. ml−1 ferret nasal lavage correlates to up to 1 × 108 viral RNA copies ml−1 (ref. 20). These comparisons suggest that the peak viral RNA copy load in ferret nasal lavages recapitulates that seen in human sputum. At present, the tissue distribution and antiviral efficacy of MK-4482/EIDD-2801 in humans are still unknown. If ferret-based inhibition data of SARS-CoV-2 transmission are predictive of the effect in humans, however, patients with COVID-19 could become non-infectious within 24–36 h after the onset of oral treatment. Treatment with MK-4482/EIDD-2801, in particular when initiated early after infection, thus has the potential to provide threefold benefits: it may mitigate the risk of progression to severe disease and accelerate recovery, ease the emotional and socio-economic toll associated with mandatory prolonged isolation and aid in rapidly silencing local outbreaks.
Ferrets (Mustela putorius furo) were used as an in vivo model to examine the efficacy of therapeutically administered oral MK-4482/EIDD-2801 against SARS-CoV-2 infection and virus transmission to uninfected contact animals. Viruses were administered to source animals through intranasal inoculation and the virus loads in nasal lavages and rectal swabs were monitored periodically as well as in respiratory tissues and a subset of organs 4 or 10 d after exposure. The virus titres were determined based on plaque assays and viral RNA copy numbers; blood samples were subjected to CBC analysis and RT–qPCR quantitation of the expression levels of select cytokine and innate antiviral effectors.
Cells and viruses
Vero E6 cells were obtained from the American Type Culture Collection (ATCC CRLK-1586) and cultured in DMEM medium supplemented with 7.5% heat-inactivated fetal bovine serum (FBS) at 37 °C with 5% CO2. SARS-CoV-2 (2019-nCoV/USA-WA1/2020) was propagated using Vero E6 cells supplemented with 2% FBS. The virus stocks were stored at −80 °C and titres were determined by plaque assay. Vero E6 cells were authenticated by morphology and susceptibility to virus infection, and routinely checked for bacterial and mycoplasma contamination at intervals of 6 months.
Virus yield reduction assay
Vero E6 cells were seeded in 12-well plates (3 × 105 cells per well) 24 h before infection. The cells were infected using a multiplicity of infection of 0.1 p.f.u. per cell. SARS-CoV-2 was allowed to adsorb for 1 h at 37 °C. Subsequently, the virus inoculum was removed and the cells were overlaid with medium containing threefold serial dilutions of NHC (50–0.68 µM) in DMEM supplemented with 2% FBS. The infected cells were incubated with compound for 48 h at 37 °C, followed by virus titration by plaque assay. The EC50 and EC90 concentrations were calculated using four-parameter variable slope regression modelling.
Samples were serially diluted (tenfold dilutions starting at a 1:10 initial dilution) in DMEM medium supplemented with 2% FBS containing Antibiotic-Antimycotic (Gibco). The serial dilutions were added to Vero E6 cells seeded in 12-well plates at 3 × 105 cells per well 24 h previously. The virus was allowed to adsorb for 1 h at 37 °C. Subsequently, the inoculum was removed and the cells were overlaid with 1.2% Avicel (FMC BioPolymer) in DMEM and incubated for 3 d at 37 °C with 5% CO2. The Avicel was removed and the cells were washed once with PBS, fixed with 10% neutral buffered formalin and plaques were visualized using 1% crystal violet.
Establishing the infectious dose
Female ferrets (6–10 months of age) were purchased from Triple F Farms. The ferrets were rested for 1 week following arrival, and then randomly assigned to groups and housed individually in ventilated negative-pressure cages in an ABSL-3 facility. To establish a suitable inoculum for the efficacy and transmission studies, the ferrets (n = 4) were inoculated intranasally with 1 × 104 and 1 × 105 p.f.u. 2019-nCoV/USA-WA1/2020 in 1 ml (0.5 ml per nare). The ferrets were anaesthetized with dexmedetomidine/ketamine before inoculation. Nasal lavages were performed on non-anaesthetized animals once a day using 1 ml PBS containing twofold concentrated Antibiotic-Antimycotic (Gibco). The nasal lavage fluids were stored at −80 °C until virus titration through plaque assays on Vero E6 cells. For blood sampling, the ferrets were anaesthetized with dexmedetomidine and approximately 0.5 ml blood was drawn from the anterior vena cava. A Vetscan HM5 (Abaxis) was used to perform CBCs in accordance with the manufacturer’s protocol. Rectal swabs were performed every 2 d. Groups of two ferrets were killed 4 and 10 d post infection and their organs were harvested to determine the virus titres and presence of viral RNA in different tissues.
The group sizes were three ferrets per condition for all animal experiments. A power calculation (P < 0.05; 80% power) predicted that this sample size was sufficient to detect a difference of 1.19 log10 p.f.u. ml−1 in virus titre in ferret nasal lavages. As no statistically informative reference datasets for the SARS-CoV-2 ferret model were available at the start of the study, we based this prospective calculation on our experience with a canine distemper virus ferret infection model that has shown a cumulative s.d. of 0.32 in our laboratory. In the transmission experiments, the ferrets were co-housed at a ratio of one source to two contact animals, three co-housing sets per condition. Incoming animals were randomly assigned to the different study groups; no blinding of investigators was performed.
In vivo efficacy of MK-4482/EIDD-2801 in ferrets
The groups of ferrets were inoculated with 1 × 105 p.f.u. 2019-nCoV/USA-WA1/2020 in 1 ml (0.5 ml per nare). At 12 h after infection, three groups of ferrets were treated b.i.d. with vehicle (1% methylcellulose) or MK-4482/EIDD-2801 at a dosage of 5 or 15 mg kg−1, respectively. At 36 h after infection, a fourth group of ferrets began receiving b.i.d. treatment with MK-4482/EIDD-2801 at a dose of 15 mg kg−1. The compound was administered via oral gavage in 1% methylcellulose. After the start of treatment, b.i.d. dosing was continued until 4 d after infection. Nasal lavages were performed on all of the ferrets every 12 h. Blood samples were obtained every 2 d after infection and stored in K2-EDTA tubes (Sarstedt CB 300). CBC analysis was performed on each blood sample in accordance with the manufacturer’s protocols. After the CBC analysis, the red blood cells were lysed with ACK buffer (150 mM NH4Cl, 10 mM KHCO3 and 0.01 mM EDTA pH 7.4) and the PBMCs were harvested and stored at −80 °C in RNAlater until further RT–qPCR analysis was performed. All of the ferrets were euthanized 4 d after infection and their organs were harvested to determine the virus titres and presence of viral RNA in different tissues.
Contact transmission of SARS-CoV-2 in ferrets
A group of six source ferrets, which were housed individually, were inoculated intranasally with 1 × 105 p.f.u. 2019-nCoV/USA-WA1/2020. Twelve hours after infection, the source ferrets were split into two groups (n = 3 each) receiving vehicle or MK-4482/EIDD-2801 treatment at a dose of 5 mg kg−1 b.i.d. by oral gavage. At 30 h post infection, each source ferret was co-housed with two uninfected and untreated contact ferrets. The ferrets were co-housed until 96 h after infection, when the source ferrets were euthanized and the contact animals were housed individually. The contact animals were monitored for 4 d after separation from the source ferrets and then killed. Nasal lavages and rectal swabs were performed on all of the ferrets every 24 h. Blood samples were collected at 0, 4 and 8 d after the source ferret infection. For all ferrets, organs were harvested to determine the virus titres and the presence of viral RNA in different tissues.
Titration of SARS-CoV-2 in tissue extracts
For virus titration, the organs were weighed and homogenized in PBS. The homogenates were centrifuged at 2,000g for 5 min at 4 °C. The clarified supernatants were harvested and used in subsequent plaque assays. For detection of viral RNA, the harvested organs were stored in RNAlater at −80 °C. The tissues were ground and the total RNA was extracted using an RNeasy mini kit (Qiagen). RNA was extracted from the rectal swabs using a ZR viral RNA kit (Zymo Research) in accordance with the manufacturer’s protocols.
SARS-CoV-2 RNA copy numbers
Detection of SARS-CoV-2 RNA was performed using the nCoV_IP2 primer–probe set (National Reference Center for Respiratory Viruses, Institut Pasteur) targeting the SARS-CoV-2 RdRp gene. An Applied Biosystems 7500 real-time PCR system using the StepOnePlus real-time PCR system was used to perform the RT–qPCR reactions. TaqMan fast virus 1-step master mix (Thermo Fisher Scientific) was used in combination with the nCoV_IP2 primer–probe set to detect viral RNA. To quantitate the RNA copy numbers, a standard curve was created using a PCR fragment (nucleotides 12669–14146 of the SARS-CoV-2 genome) generated from viral complementary DNA using the nCoV_IP2 forward primer and the nCoV_IP4 reverse primer. The RNA values were normalized to the weights of the tissues used.
Systemic interferon and cytokine profiling
The relative expression of interferon, ISGs and cytokines was determined by real-time PCR analysis. RNA was extracted from PBMCs that were harvested at various time points after infection. Complementary DNA was reverse transcribed with SuperScript III (Invitrogen) using oligo-dT primers and analysed by real-time PCR using Fast SYBR Green master mix (Applied Biosystems). The signals were normalized to glyceraldehyde-3-phosphate dehydrogenase messenger RNA, analysed using the comparative threshold cycle (ΔΔCt) method and expressed relative to day 0 of infection for each respective animal. The sequences of the primers used for the analyses are shown in Supplementary Table 13.
Statistics and reproducibility
The Microsoft Excel (versions 16.42 and 16.43) and GraphPad Prism (version 8.4.3) software packages were used for most of the data collection and analysis, respectively. Reverse transcription RT–qPCR data were collected and analysed using the StepOnePlus (version 2.1; Applied Biosystems) software package. The final figures were assembled using Adobe Illustrator (version CS6). One- or two-way ANOVAs with Dunnett’s, Tukey’s or Sidak’s multiple comparisons post-hoc tests without further adjustments were used to evaluate statistical significance when more than two groups were compared or datasets contained two independent variables, respectively. The specific statistical test applied to individual studies is specified in the figure legends. The Source Data files summarize the statistical analyses (effect size, degrees of freedom and P values) of the respective datasets. Effect sizes between groups in the ANOVAs were calculated as η2 = (SSeffect) / (SStotal) for one-way ANOVA and ω2 = (SSeffect − (dfeffect)(MSerror)) / MSerror + SStotal for two-way ANOVA; SSeffect, sum of squares for the effect; SStotal, sum of squares for total; dfeffect, degrees of freedom for the effect; MSerror, mean squared error. To determine the antiviral potency and cytotoxicity, the effective concentrations were calculated from dose-response datasets through four-parameter variable slope regression modelling; the values have been expressed with 95% confidence intervals when possible. A biological repeat refers to measurements taken from distinct samples, and the results obtained for each individual biological repeat are shown in the figures along with the exact size (n, number) of biologically independent samples, animals or independent experiments. The measure of the centre (connecting lines and columns) is the mean throughout. The error bars represent the s.d. throughout. For all experiments, the statistical significance level α was set to <0.05; exact P values are shown in individual graphs or Supplementary Tables wherever possible.
All animal work was performed in compliance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the Animal Welfare Act Code of Federal Regulations. Experiments with SARS-CoV-2 involving ferrets were approved by the Georgia State Institutional Animal Care and Use Committee under protocol A20031. All experiments using infectious SARS-CoV-2 were approved by the Georgia State Institutional Biosafety Committee under protocol B20016 and performed in BSL-3/ABSL-3 facilities at the Georgia State University.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
All of the data generated or analysed during this study are included in this published article. Source data are provided with this paper.
This study does not use custom codes. All of the commercial computer codes and algorithms used are specified in the Methods section.
Rodriguez Mega, E. COVID has killed more than one million people. How many more will die? Nature https://doi.org/10.1038/d41586-020-02762-y (2020).
Martinot, M. et al. Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa1474 (2020).
Humeniuk, R. et al. Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. Clin. Transl. Sci. 13, 896–906 (2020).
Toots, M. et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 11, eaax5866 (2019).
Toots, M. & Plemper, R. K. Next-generation direct-acting influenza therapeutics. Transl. Res. https://doi.org/10.1016/j.trsl.2020.01.005 (2020).
Salajegheh Tazerji, S. et al. Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review. J. Transl. Med. 18, 358 (2020).
Oreshkova, N. et al. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Euro Surveill. https://doi.org/10.2807/1560-7917.ES.2020.25.23.2001005 (2020).
Enserink, M. Coronavirus rips through Dutch mink farms, triggering culls. Science 368, 1169 (2020).
Oude Munnink, B. B. et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science https://doi.org/10.1126/science.abe5901 (2020).
Toots, M. et al. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl. Res. 218, 16–28 (2020).
Yoon, J. J. et al. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob. Agents Chemother. 62, e00766-18 (2018).
Urakova, N. et al. β-d-N4-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J. Virol. 92, e01965-17 (2018).
Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883 (2020).
Han, K. et al. Lung expression of human ACE2 sensitizes the mouse to SARS-CoV-2 infection. Am. J. Respir. Cell Mol. Biol. https://doi.org/10.1165/rcmb.2020-0354OC (2020).
Bruschke, C. Nature and Food Quality Ministry of Agriculture (Ministry of Agriculture, 2020).
Schlottau, K. et al. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. Lancet Microbe 1, e218–e225 (2020).
Richard, M. et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat. Commun. 11, 3496 (2020).
Davies, N. G. et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat. Med. 26, 1205–1211 (2020).
Agostini, M. L. et al. Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol. 93, e01348-19 (2019).
Shi, J. et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 368, 1016–1020 (2020).
Park, S. J. et al. Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets. mBio 11, e01114-20 (2020).
Kutter, J. S. et al. SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance. Preprint at bioRxiv https://doi.org/10.1101/2020.10.19.345363 (2020).
Merck & Co. (Ridgeback Biotherapeutics) and Drug Innovations at Emory (DRIVE) – MK-4482 (formerly EIDD-2801). Genetic Engineering and Biotechnology News https://www.genengnews.com/covid-19-candidates/ridgeback-biotherapeutics-and-drug-innovations-at-emory-drive/(2020).
Painter, G. R. et al. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal Venezuelan equine encephalitis virus infection. Antivir. Res. 171, 104597 (2019).
Les, A., Adamowicz, L. & Rode, W. Structure and conformation of N4-hydroxycytosine and N4-hydroxy-5-fluorocytosine. A theoretical ab initio study. Biochim. Biophys. Acta 1173, 39–48 (1993).
Crotty, S., Cameron, C. E. & Andino, R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl Acad. Sci. USA 98, 6895–6900 (2001).
Desmyter, J., Melnick, J. L. & Rawls, W. E. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J. Virol. 2, 955–961 (1968).
Cox, R. M. et al. Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase. Nat. Microbiol. https://doi.org/10.1038/s41564-020-0752-7 (2020).
Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020).
We thank M. Kumar for providing an aliquot of 2019-nCoV/USA-WA1/2020 stock, members of the GSU High Containment Core and the Department for Animal Research for support, and J. Sourimant and A. L. Hammond for critical reading of the manuscript. This work was supported, in part, by Public Health Service grant nos AI071002 (to R.K.P.) and AI141222 (to R.K.P.) from the NIH/NIAID. The funders had no role in the study design, data collection and interpretation or the decision to submit the work for publication.
The authors declare no competing interests.
Peer review statement Nature Microbiology thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ferrets were inoculated intranasally with 1 × 104 (blue) or 1 × 105 p.f.u. (black) of 2019-nCoV/USA-WA1/2020. a, Analysis of bronchioalveolar lavages (BALF) and four lung lobes (right (R.) and left (L.) cranial and caudal) per ferret. BALF and tissues samples were harvested 4 (n = 2 biologically independent animals) and 10 (n = 2 biologically independent animals) days after infection. The number of independent biological repeats is shown. Symbols represent independent biological repeats (individual animals).
Extended Data Fig. 2 Experimental means and intergroup comparison of in vivo efficacy study results of MK-4482/EIDD-2801 in SARS-CoV-2-infected ferrets.
a, Comparison of SARS-CoV-2 titres in nasal lavages of SARS-CoV-2 infected ferrets treated with different doses and dosing regimens. Mean virus titres ± SD are shown for different study days (days pI). LOD was 10 p.f.u. (a-b). Samples below LOD were plotted as 9 p.f.u. b, SARS-CoV-2 titres in nasal turbinates of ferrets from (a). Mean virus titres ± SD are shown. L.O.D. was 10 p.f.u. (a-b). c, Viral RNA detected in nasal turbinates of ferrets from (a). Mean RNA copy numbers ± SD are shown. Statistical significance was determined between different treatment groups. LOD was 1 RNA copy, samples below LOD were plotted as 1 RNA copy. Statistical analysis was performed by two-way (a) or one-way (b-c) ANOVA with Tukey’s multiple comparison post-hoc test. P values are shown. (*) denotes samples where one or two repeats were below LOD. (**) denotes all three repeats for at least one dosing group were below LOD.
Extended Data Fig. 3 Interferon induction and cytokine profiling of SARS-CoV-2 ferrets treated with MK-4482/EIDD-2801.
Ferrets (n = 3 biologically independent animals) were infected intranasally with 1 × 105 p.f.u. 2019-nCoV/USA-WA1/2020 and either gavaged with vehicle (black (a-f)) or treated b.i.d. with MK-4482/EIDD-2801 commencing 12 (5 mg/kg (blue (a-f)) and 15 mg/kg (orange (a-f)) or 36-hours (15 mg/kg; red (a-f)) after infection. a-f, Selected interferon and cytokine expression levels in PBMCs relative to day 0. Blood samples of animals treated with MK-4482/EIDD-2801 or vehicle as specified were collected every two days after infection and PBMCs analysed by RT-qPCR. Statistical analysis of changes relative to day 0 by two-way ANOVA with Dunnett’s post-hoc multiple comparison test. The number of independent biological repeats (n; individual animals) is shown. In all panels, symbols represent independent biological repeats (individual animals), lines connect group means ± SD.
Ferrets (n = 3 biologically independent animals) were infected intranasally with 1 × 105 p.f.u. 2019-nCoV/USA-WA1/2020 and either gavaged with vehicle (black (a-f)) or treated b.i.d. with MK-4482/EIDD-2801 commencing 12 (5 mg/kg (blue (a-f)) and 15 mg/kg (orange (a-f)) or 36-hours (15 mg/kg; red (a-f)) after infection. a-d, Blood samples were collected every two days after infection and complete blood counts determined. No abnormal values were observed in all parameters tested, including total WBCs (a), lymphocytes (b), neutrophils (c), and platelets (d). The shaded green areas represent normal Vetscan HM5 lab values. The number of independent biological repeats (n; individual animals) is shown for each subpanel. Symbols represent independent biological repeats (individual animals), lines connect group means ± SD.
Numerical source data and statistical analyses for experiments shown in Fig. 1.
Experimental source data and statistical analyses for experiments shown in Fig. 2.
Numerical source data and statistical analyses for experiments shown in Fig. 3.
Numerical source data for experiments shown in ED Fig. 1.
Statistical source data for experiments shown in ED Fig. 2.
Numerical source data and statistical analyses for experiments shown in ED Fig. 3.
Numerical source data for experiments shown in ED Figure 4.
About this article
Cite this article
Cox, R.M., Wolf, J.D. & Plemper, R.K. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol 6, 11–18 (2021). https://doi.org/10.1038/s41564-020-00835-2
This article is cited by
Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
Nature Communications (2023)
Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
Infectious Diseases and Therapy (2023)
European Journal of Clinical Pharmacology (2023)
Topics in Current Chemistry (2023)
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Infectious Diseases and Therapy (2023)